Characteristics of patients with HGBL vs non-HGBL at the date of eligibility
| Eligibility, N = 228 . | P value . | ||
|---|---|---|---|
| Characteristic . | HGBL, n = 73 . | Non-HGBL, n = 155 . | |
| Age, median (range), y | 62 (26-78) | 62 (17-79) | .743 |
| Male sex, n (%) | 47 (64.4) | 100 (64.5) | 1.000 |
| ECOG ≥2, n (%) | 9 (12.3) | 23 (14.8) | .836 |
| Ann Arbor stage III or later, n (%) | 63 (86.3) | 125 (80.6) | .259 |
| LDH elevated (>1N), n (%) | 52 (71.2) | 119 (76.8) | .509 |
| aaIPI ≥2, n (%) | 45 (61.6) | 94 (60.6) | .417 |
| Previous lines, median (IQR) | 2 (2-7) | 2 (2-9) | .650 |
| Previous auto-HSCT, n (%) | 6 (8) | 23 (15) | .203 |
| Bridging therapy, n (%) | 64 (87.7) | 142 (91.6) | .346 |
| Eligibility, N = 228 . | P value . | ||
|---|---|---|---|
| Characteristic . | HGBL, n = 73 . | Non-HGBL, n = 155 . | |
| Age, median (range), y | 62 (26-78) | 62 (17-79) | .743 |
| Male sex, n (%) | 47 (64.4) | 100 (64.5) | 1.000 |
| ECOG ≥2, n (%) | 9 (12.3) | 23 (14.8) | .836 |
| Ann Arbor stage III or later, n (%) | 63 (86.3) | 125 (80.6) | .259 |
| LDH elevated (>1N), n (%) | 52 (71.2) | 119 (76.8) | .509 |
| aaIPI ≥2, n (%) | 45 (61.6) | 94 (60.6) | .417 |
| Previous lines, median (IQR) | 2 (2-7) | 2 (2-9) | .650 |
| Previous auto-HSCT, n (%) | 6 (8) | 23 (15) | .203 |
| Bridging therapy, n (%) | 64 (87.7) | 142 (91.6) | .346 |
1N, normal range; aaIPI, age-adjusted IPI; ECOG PS, Eastern Cooperative Oncology Group performance status; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range.